Clinical observations and physiological data supporting a vascular response as a mechanism of the novel woundhealing agent, OPAL A

G. Mitchell, T. Windegger, F.D. Russell





Principles of standard care

- Debridement
- Infection control
- Moist clean environment
- Pressure bandaging for venous ulceration

The OPAL Process

- Pulped pawpaw
- Filtrates extracted from pulps prepared according to the OPAL Process
 - Involves heat and alkalinisation. Filtrate extracted.
- Filtrates mixed together and preservative added
- Product named OPAL A

Ulcer treatment

- Ulcer treatment evolved to:
 - Filtrate applied to wound
 - Filtrate in ointment base applied to skin around and proximal to wound
 - Daily application of both

Requirements for wound healing

Adequate oxygen,
Adequate Nutrients
Intact immune system

Good Arterial blood supply Good venous blood supply

Inhibitors of wound healing

Inadequate nutrition
Impaired venous circulation
Impaired systemic immune
response



Left first and second toes 15 May 2008 85 yr woman. Generalised arteriopathy. Sudden breakdown of skin from poor arterial supply made worse with cold weather.

OPAL 001 filtrate applied to wound, cream to foot and leg to knee.



Date 29 May 2009 Two weeks of treatment Rapid improvement.



24 June 2008. Six weeks Second toe almost healed. First toe. Odd lesion is exogenous nail.



Left temple marginally viable skin graft. Graft repair of removal of major skin cancer.

OPAL 001 used starting 24 April 2008



29 May 2008
Five weeks.
Graft now fully viable. Ulcers at margins healing



24 June 2008
Eight weeks
Central ulcer closing.
Graft skin now normal.

5/8/09

0 cm 1 2 3 4 5 6 7 8 9 10 11

5 August 2008

Three months
Graft fully healed

Diabetic ulceration of toes



55 Yr male. Date 20th April.
Diabetic, alcoholic. Poor nutrition
The toe at the commencement of treatment. The tip is necrotic and probably infected. The nail is grossly abnormal.



Five weeks Date 22 May 2003 Toe virtually healed. Toenail removed and new nail forming.

Improved microcirculation





Left outer mid-shin 16 Nov08

Elderly man.
Chronic
extensive
DVTs,
Psoriasis.

Healing ulcer

Compromised skin





Skin quality vastly improved

Hypothesis

That a major contributor to OPAL A's apparent wound healing property is vasodilation.

Does OPAL A mediate NO-dependent relaxation of blood vessels?







OPAL A mediates vasorelaxation in human umbilical vein by production of NO

No Alkalinisation of OPAL A (Bath pH = 7.6)

Alkalinised OPAL A (Bath pH adjusted to 7.4 to 7.8)






Time control (water)

OPAL A + L-NAME


△ OPAL A

Endothelial cells remain intact in the bath, and OPAL A is non-toxic to the cells


Immunohistochemistry showing intact endothelium




MTT cell viability assay



Noradrenaline (NA) maintains basal vascular tone




OPAL A initially attenuates, then facilitates oxidation of NA




Oxidation of NA: requirement for O₂, metal ions and a protein

- OPAL A
- NaHCO₃
- \triangle NaHCO₃ + N₂
- OPAL A + N_2

- OPAL A
- OPAL A + 1mM EDTA
- OPAL A
- OPAL A (heat treated, 10 min, 100°C)




Does OPAL A metabolise NA to reduce basal tone?



Isolated Rabbit Aorta: OPAL A causes a small reduction in efficacy of NA. No change in potency.

Developed tension (% 60 mM KCI)



Conclusions

- OPAL A provides effective wound resolution where hypoperfusion at the arteriolar level contributes to wound aetiology
- OPAL A produced nitric oxide-dependent vasorelaxation in a human blood vessel preparation. Improved perfusion at the wound site may contribute to the observed clinical improvements.
- Whilst OPAL A appeared to oxidise NA, this caused only a small reduction in efficacy of NA, and no significant change in potency.

Acknowledgements

University of the Sunshine Coast Dr. Denis Podger

Nambour General Hospital, Qld Nurses and Surgeons

The Prince Charles Hospital, Qld Dr. John Fraser

Limestone Medical Centre, Ipswich Patients and staff

Phoenix Eagle Company Pty. Ltd.
Mark Richardson
Dr. Mark Woolley